Novo Nordisk announced on March 5, 2024, that its drug semaglutide 1.0 mg significantly reduces the risk of kidney disease-related events by 24% in patients with type 2 diabetes and chronic kidney disease, based on the FLOW trial results. The trial ended early on October 10, 2023, due to positive efficacy results with 3,533 participants enrolled.